Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Taylor

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|July 22, 2020
Design and Synthesis of a Highly Selective and <i>In Vivo</i>-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of ProteinsAlex Preston, Stephen Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase ActivatorChristopher G Thomson, Thomas D Aicher, Weiwei Cheng, et al.
Journal of Medicinal Chemistry|July 7, 2021
Identification of a Series of <i>N</i>-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) ProteinsLee A Harrison, Stephen J Atkinson, Anna Bassil, et al.
Journal of Medicinal Chemistry|August 16, 2011
Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral doseEmmanuel H Demont, Sandra Arpino, Rino A Bit, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart RateEmmanuel H Demont, Benjamin I Andrews, Rino A Bit, et al.
Journal of Medicinal Chemistry|August 14, 2020
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative PhenotypeChristopher R Wellaway, Paul Bamborough, Sharon G Bernard, et al.
ACS Medicinal Chemistry Letters|August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) FamilyAlex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry|January 12, 2016
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral DosesEmmanuel H Demont, James M Bailey, Rino A Bit, et al.
Journal of Medicinal Chemistry|September 25, 2014
The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitorRomain Gosmini, Van Loc Nguyen, Jérôme Toum, et al.
Journal of Medicinal Chemistry|July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) InhibitorJonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|July 22, 2020
Design and Synthesis of a Highly Selective and <i>In Vivo</i>-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of ProteinsAlex Preston, Stephen Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase ActivatorChristopher G Thomson, Thomas D Aicher, Weiwei Cheng, et al.
Journal of Medicinal Chemistry|July 7, 2021
Identification of a Series of <i>N</i>-Methylpyridine-2-carboxamides as Potent and Selective Inhibitors of the Second Bromodomain (BD2) of the Bromo and Extra Terminal Domain (BET) ProteinsLee A Harrison, Stephen J Atkinson, Anna Bassil, et al.
Journal of Medicinal Chemistry|August 16, 2011
Discovery of a brain-penetrant S1P₃-sparing direct agonist of the S1P₁ and S1P₅ receptors efficacious at low oral doseEmmanuel H Demont, Sandra Arpino, Rino A Bit, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart RateEmmanuel H Demont, Benjamin I Andrews, Rino A Bit, et al.
Journal of Medicinal Chemistry|August 14, 2020
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative PhenotypeChristopher R Wellaway, Paul Bamborough, Sharon G Bernard, et al.
ACS Medicinal Chemistry Letters|August 25, 2020
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) FamilyAlex Preston, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry|January 12, 2016
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral DosesEmmanuel H Demont, James M Bailey, Rino A Bit, et al.
Journal of Medicinal Chemistry|September 25, 2014
The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitorRomain Gosmini, Van Loc Nguyen, Jérôme Toum, et al.
Journal of Medicinal Chemistry|July 24, 2020
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) InhibitorJonathan T Seal, Stephen J Atkinson, Helen Aylott, et al.
Pageof 9